Otros idiomas AstraZeneca Pharma India Limited NSE India S.E.

Acciones

ASTRAZEN

INE203A01020

Mercado cerrado - NSE India S.E. Otros sitios de cotización 13:43:51 15/05/2024			Varia. Cinco días.	Varia. 1 de enero.
5.491 ^INR	+0,62 %		+4,79 %	-0,64 %

08/04	AstraZeneca Pharma India Limited aprueba el nombramiento de Bhavana Agrawal como Directora y Directora a Tiempo Completo	CI
25/03	AstraZeneca Pharma India Limited nombra a Vinay Sharma Jefe de la Unidad de Negocio - Enfermedades Raras, con efecto a partir del 1 de julio de 2024	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

AstraZeneca Pharma India Limited Approves Appointment of Bhavana Agrawal as Director and Whole Time Director	08/04
AstraZeneca Pharma India Limited Appoints Vinay Sharma as Business Unit Head - Rare Disease, Effective July 1, 2024	25/03
AstraZeneca, Mankind Pharma Tie Up for Exclusive Distribution of Asthma Drug Symbicort in India	11/03
Astrazeneca Pharma India Ltd and Mankind Pharma Partner to Accelerate Access to Asthma Medicine for Patients in India	11/03
Astrazeneca Pharma India Limited Announces Board Changes	20/02
AstraZeneca Pharma India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
AstraZeneca Pharma India Limited Announces Board Changes	08/02
AstraZeneca Pharma India Limited Announces Directorate Appointments	07/02
AstraZeneca Gets Indian Drug Regulator's Nod to Import Andexanet Alfa Powder for Solution for Infusion	22/01
Astrazeneca Pharma to Launch Breast Cancer Treatment Drug in India in January 2024	21/12
India's Nifty set for muted open after steep drop	21/12
Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)	09/11
AstraZeneca Pharma India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
AstraZeneca Gets Indian Drug Regulator's Nod to Import Pharmaceutical Formulations for Palivizumab	02/10/23
Astrazeneca Pharma India Limited Receives Permission to Import Pharmaceutical Formulations Of New Drug For Sale Or For Distribution In Form CT-20 From Central Drugs Standard Control Organisation For Palivizumab	30/09/23
AstraZeneca Pharma India Limited Announces Management Changes	29/09/23
Astrazeneca Pharma India Limited Announces Retirement of Rajesh Marwaha as Whole-Time Director	29/09/23
AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023	15/09/23
AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023	17/08/23
AstraZeneca Pharma India Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/08/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas AstraZeneca Pharma India Limited NSE India S.E.

Acciones

ASTRAZEN

INE203A01020

Otros idiomas

Filtros